Born from the cooperation and joint work of scientists from the CNRS, INSA and a practicing biologist, Dendris is developing a powerful and automated syndromic molecular diagnostic solution for medical biology laboratories. “We work mainly with laboratories and large molecular biology technical platforms in university hospitals and private laboratories” says Nathalie Vandenbroucke, CEO of Dendris. This innovative culture-free technology enables rapid and efficient diagnosis of bacterial, viral and fungal infectious diseases. “It is a process that has been underway for a long time, in particular for virology but that, tomorrow, will accelerate for other disciplines that still go through traditional culture” says biologist Richard Fabre.
The third-generation biochip developed by Dendris simplifies and unlocks the power of research DNA chips for routine medical diagnosis. “We were able to achieve this thanks to two innovations: dendrimers, which cover the surface of the chip, and an innovative readout based on artificial intelligence,” explains Richard Fabre.
Towards an acceleration of infectious diseases
Considered a developing standard, this innovative concept aims to support and facilitate the advent of mass molecular biology through the use of these cutting-edge technologies. “We have all seen the impact that Covid-19 has had in general. It is clear that in the next ten or fifteen years. There will be new infectious diseases that will emerge in addition to the previous ones, so it is very important to be armed against these threats ” says Ricardo Fabre.
If the product developed by Dendris has already revealed its effectiveness, its commercialization has only just begun. Dendris now wants to be able to develop in France before reaching the European and international market more widely.
Dendris’s LinkedIn Page
This content was produced in association with OpenMedias. The BFM Business editorial team was not involved in the production of this content.
Source: BFM TV
